Bemethyl 125mg – 60 capsules Product Information
Bemethyl 125 mg — 60 oral research capsules. Bemethyl (2-ethylthiobenzimidazole hydrobromide) is the founding member of the actoprotector class — a category of synthetic adaptogenic-metabolic compounds developed by the Soviet-era Bekhtereva Institute that occupy a pharmacological niche unlike anything in Western medicine. Bemethyl is clinically registered in the Russian Federation for use in extreme physical and cognitive stress conditions: military, aerospace, deep-sea diving, post-disaster rescue, and elite athletic performance research. It produces a measurable enhancement of physical and mental work capacity under hypoxic, thermal and physically demanding conditions through accelerated gluconeogenesis and direct mitochondrial-respiratory-chain optimization — a mechanism profile that has no Western pharmaceutical equivalent. RESEARCH USE ONLY · Not for human or veterinary use. For laboratory and collector purposes only. Purity ≥ 99 % (HPLC) — third-party tested, CoA on file Form Research capsules Content 125 mg Bemethyl (hydrobromide) per capsule Total 60 capsules per bottle (7.5 g total) Packaging Sealed bottle with tamper-evident closure Storage Room temperature, dry, protected from light Molecular formula C₉H₁₀N₂S · HBr Molecular weight ≈ 259.16 g·mol⁻¹ (hydrobromide); 178.25 g·mol⁻¹ (free base) IUPAC name 2-(ethylsulfanyl)-1H-benzimidazole hydrobromide CAS number 61-66-5 (free base); 36770-58-0 (HBr salt) Synonyms Antihypoxin; 2-ethylthiobenzimidazole; actoprotector Research Overview Bemethyl is a 2-ethylthio-substituted benzimidazole derivative developed in the Soviet Union in the 1960s by Vladimir Vinogradov and clinically registered in the Russian Federation as an actoprotector — a uniquely Soviet pharmacological category referring to compounds that increase the body’s capacity for prolonged work under adverse environmental conditions [1]. Mechanistically, bemethyl accelerates hepatic gluconeogenesis and enhances oxidative phosphorylation efficiency at the mitochondrial level — improving substrate utilization and ATP yield under conditions of hypoxia, thermal stress and prolonged physical exertion [1,2]. Russian-language clinical literature reports applications in military exercise tolerance, post-disaster physical performance recovery, deep-sea diver decompression-stress mitigation, and elite-athlete training tolerance studies [2,3]. The molecule has been explicitly distinguished from psychostimulants and traditional adaptogens (Rhodiola, Eleutherococcus): unlike stimulants, it does not increase catecholaminergic drive; unlike herbal adaptogens, its mechanism is metabolic rather than HPA-axis-modulating. Bemethyl has emerged in Western research interest as the most pharmacologically interesting representative of this Soviet-developed class. Primary Research Areas Actoprotector pharmacology — the founding member of the Soviet-developed actoprotector class; the canonical chemical probe for the mitochondrial-respiratory-chain-optimization approach to physical work capacity [1,2]. Hypoxia tolerance and altitude research — documented enhancement of work capacity under hypobaric and chemically induced hypoxia models [1,2]. Physical performance and endurance — clinical-research applications in military, aerospace and elite athletic populations under extreme operational conditions [2,3]. Mitochondrial bioenergetics — modulator of oxidative phosphorylation efficiency and gluconeogenic substrate utilization [1]. Post-stress recovery models — investigated for accelerated recovery from prolonged physical exertion, decompression stress and thermal stress [3]. References Oliynyk S, Oh S. The pharmacology of actoprotectors: practical application for improvement of mental and physical performance. Biomol Ther (Seoul). 2012;20(5):446–456. Smirnov AV. Antihypoxants in emergency medicine. Anesteziol Reanimatol. 1998;(2):50–55. Lukyanova LD, Germanova EL, Kopaladze RA. Development of resistance of an organism under various conditions of hypoxic preconditioning: role of the hypoxic period and reoxygenation. Bull Exp Biol Med. 2009;147(3):400–404.
